The drug dolutegravir is a widely used part of combination therapy for HIV treatment. Dolutegravir belongs to a class of drugs called integrase inhibitors; it is powerful and generally well tolerated. Dolutegravir is sold under the following brand names and fixed-dose combinations:
[T]he primary purpose of Thanksgiving is expressing gratitude, a very healthy impulse that makes everyone happier -- and since this is an ID blog, here are bunch of things ID and HIV specialists can be thankful for over the past year.
By 2020, about 70% of people living with HIV will be over the age of 50, and as they age, they will inevitably be administered even more medications. Long-term survivors have taken a variety of different antiretrovirals for decades, to which have been added other drugs to control not only complications of HIV but also side effects of the medications themselves, including hypertension, diabetes, cognitive impairment, hypogonadism, bone density problems, and high cholesterol. Because normal aging typically results in a variety of other conditions, those who are aging and living with HIV find themselves taking more pills more often.
In a study of more than 1,400 women living with HIV, nearly 30% did not achieve viral suppression and some groups of women had greater challenges with adherence and staying in care.
The HIV drug class called "non-nucleoside reverse transcriptase inhibitors," or NNRTIs, must have something of an inferiority complex.
California's expansion of Medicaid under the Affordable Care Act enabled many low-income HIV patients to get health insurance previously denied to them. Still, those with mental health needs, who had been receiving coordinated care through a separate federal program, suddenly faced gaps in treatment, payment disputes and doctors who had little understanding of life with HIV.
There are multiple reasons why re-entry into communities from prison for black men with HIV is a difficult proposition, according to a recent study published in Social Science and Medicine. The researchers show that the intersectionality framework is applicable to understanding the challenges these men face after serving time in prison.
Earlier this year, I wrote a piece about friends and colleagues of mine who have left HIV clinical practice. Something about it touched a nerve. It's one of the most commented-on pieces in the history of this blog.
The International AIDS Conference -- or "AIDS 2018" -- returned to Amsterdam for the first time since 1992.
The latest HIV drug approval from the FDA came this past week with the release of a single-tablet treatment containing the following drugs:
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.